NCT03687632View on ClinicalTrials.gov

ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 10, 2019

Primary Completion Date

August 18, 2020

Study Completion Date

August 25, 2020

Conditions
Persistent Corneal Epithelial Defect
Interventions
BIOLOGICAL

ST266

1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).

Trial Locations (8)

15213

Univesity of Pittsburgh, Pittsburgh

19104

University of Pennsylvania, Philadelphia

21201

University of Maryland, Baltimore

26506

University of West Virginia, Morgantown

41017

Cincinnati Eye Institute, Edgewood

44195

Cleveland Clinic, Cleveland

46260

Price Vision Group, Indianapolis

02111

Tufts Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Noveome Biotherapeutics, formerly Stemnion

INDUSTRY

NCT03687632 - ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects | Biotech Hunter | Biotech Hunter